Harmony Biosciences Shares Fall 7% as Wakix Patent Arguments Unfold
Photo: TokenPost
Harmony Biosciences Holdings, Inc. (HRMY) shares fell 7% on Oct. 22 as closing arguments were underway in a patent dispute over Wakix, the company’s drug. The arguments were taking place Thursday in Wilmington, Delaware, in ANDA patent litigation between Harmony and AET Pharma. Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
